Nivolumab in non-small-cell lung cancer with EGFR mutation

Ann Oncol. 2018 Mar 1;29(3):777-778. doi: 10.1093/annonc/mdx745.

Authors

H Yoshida¹, Y H Kim², H Ozasa¹, H Nagai¹, Y Sakamori¹, T Tsuji¹, T Nomizo¹, Y Yasuda¹, T Funazo¹, T Hirai¹

Affiliations

¹ Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
² Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan. Electronic address: [email protected].

PMID: 29161357
DOI: 10.1093/annonc/mdx745

No abstract available

MeSH terms

Adult
Aged
Antineoplastic Agents, Immunological / therapeutic use*
Carcinoma, Non-Small-Cell Lung / drug therapy*
Carcinoma, Non-Small-Cell Lung / genetics
ErbB Receptors / genetics
Female
Humans
Lung Neoplasms / drug therapy*
Lung Neoplasms / genetics
Male
Middle Aged
Mutation
Nivolumab / therapeutic use*

Substances

Antineoplastic Agents, Immunological
Nivolumab
EGFR protein, human
ErbB Receptors